The first pharmaceutical product ever manufactured in orbit and returned to Earth is a small, structured crystal of the HIV medication ritonavir. It landed in the Utah desert in February 2024, packed inside a heat-shielded capsule that had spent eight months in space. For Varda Space Industries, that payload was more than a technical demonstration. It was the opening argument for a new industrial category: using microgravity as a tool to engineer better medicines, starting with formulations that are difficult or impossible to crystallize on the ground [Perplexity Sonar Pro Brief].
Since that first return, Varda has methodically turned a science experiment into a repeatable operation. By July 2025, the company had completed three successful launch-and-return missions [Reuters, July 2025]. Its W-4 capsule spent nearly a full year in orbit before reentering in May 2026 [Varda Space Industries]. The cadence is deliberate, a proof point for pharmaceutical partners who need reliability above all else. With a fresh $250 million Series D closed in September 2026 at a $1.6 billion valuation, Varda is now tasked with moving from proving the concept to scaling the business [933thedrive.com, Sep 2026].
The microgravity wedge
Varda's core thesis is that the absence of gravity can solve specific, high-value problems in drug development. On Earth, convection currents and sedimentation can interfere with the formation of pure, stable crystal structures for certain complex molecules. In microgravity, materials can combine more uniformly, potentially yielding pharmaceutical ingredients with improved solubility, bioavailability, or shelf life. The company's initial focus is on this crystallization process, offering it as a service to biopharma clients [Perplexity Sonar Pro Brief].
Its hardware, the W-Series, is a two-part system. An orbital manufacturing module, equipped with in-situ sensors like video microscopy and Raman spectroscopy, houses and monitors the experiments [Varda Space Industries, retrieved 2024]. A separate, proprietary reentry capsule then brings the finished product back through the atmosphere. Varda designs and builds both elements internally, while partnering with launch providers like SpaceX and using Rocket Lab's spacecraft bus for in-orbit operations [Perplexity Sonar Pro Brief]. This vertical integration over the critical payload and return segments is a key part of its claimed control over quality and schedule.
A dual-track business model
While pharmaceuticals represent the long-term vision, Varda has built a parallel revenue stream that helps fund the mission. The same reentry capsule that brings back drug crystals is also a high-performance test platform for government and defense agencies. The company sells access for hypersonic flight testing and thermal protection system development, work that includes contracts like the U.S. Air Force Research Laboratory's Prometheus program [Perplexity Sonar Pro Brief].
This dual-use strategy provides near-term capital and flight heritage. Each mission can carry both commercial and government payloads, de-risking the operational tempo. The company has also secured a vehicle operator license from the Federal Aviation Administration, clearing its capsules for reentries through 2029 [Varda Space Industries]. The funding history shows investors backing both tracks of the plan.
2020 Seed | 9 | M USD
2021 Early Round | 9 | M USD
2024 Series B | 90 | M USD
2025 Series C | 187 | M USD
2026 Series D | 250 | M USD
The team and the traction
Varda was founded in 2021 by Will Bruey, a former SpaceX engineer, and Delian Asparouhov, a partner at Founders Fund. Daniel Marshall, identified as a co-founder and the company's chief scientist in earlier profiles, brought scientific expertise to the trio [Perplexity Sonar Pro Brief]. The team has since grown to approximately 269 employees, reflecting the complex hardware-software-biology integration the model requires [LeadIQ, retrieved 2026].
Traction is measured in successful returns and regulatory milestones. The ritonavir mission navigated a months-long regulatory process with the FAA, setting a precedent. The company's most recent funding round, led by Lux Capital and Natural Capital, brings its total disclosed capital to about $598 million [933thedrive.com, Sep 2026]. This war chest is earmarked for scaling operations, with the company planning to launch two more capsules, W-8 and W-9, on a SpaceX Falcon 9 [Fierce Pharma].
The path to economic gravity
The technical and regulatory hurdles of space-based manufacturing are immense, and Varda has cleared the first set. The next challenge is economic. The company must demonstrate that the superior drug properties achievable in microgravity justify the significant cost and complexity of a space mission. This requires moving beyond one-off experiments to recurring contracts with large pharmaceutical companies, a commercial motion that remains unproven at scale.
Varda also operates in a nascent competitive field. While companies like Redwire and Space Forge explore in-space manufacturing, and The Exploration Company develops reusable cargo spacecraft, Varda's integrated focus on pharmaceuticals and hypersonic testing is distinct. Its most significant competition may not be other space startups, but continual advances in terrestrial pharmaceutical engineering that could achieve similar ends without ever leaving the ground.
The company's plausible answer is specialization. By focusing narrowly on crystalline drug formulations where microgravity offers a definitive advantage, Varda aims to become an essential, if exotic, tool in the pharma R&D toolkit. Its government work provides a revenue buffer and flight cadence as it builds that commercial case.
The patient population
For all the talk of capsules and orbits, the ultimate endpoint for Varda's pharmaceutical work is a patient. The disease states in its sights are those treated by complex small-molecule drugs where solubility and stability are limiting factors. This includes certain antivirals, like the ritonavir it has already processed, and potentially oncology therapies where bioavailability can dictate efficacy and side effects.
The standard of care today for these patients is a medicine formulated on Earth, using techniques like spray drying, lipid nano-encapsulation, or co-crystallization with other agents to improve performance. These methods are well-understood and scalable, but they have physical limits. If Varda's thesis holds, its contribution won't be a new drug, but a better version of an existing one: a pill that works more reliably, requires a lower dose, or lasts longer on the shelf because its fundamental structure was assembled in the quiet of space.
The next twelve months will be about transitioning from demonstration to deployment. Watch for announced partnerships with pharmaceutical names, details on the payloads for the W-8 and W-9 missions, and any data shared on the clinical-grade characteristics of space-manufactured materials. Each successful, uneventful return makes the extraordinary a little more routine, and brings the industry closer to answering the fundamental question: when is going to space the most practical way to make a medicine better?
Sources
- [Perplexity Sonar Pro Brief] Varda Space Industries company brief
- [Reuters, July 2025] Varda Space raises $187 million to accelerate development of drugs in space | https://www.reuters.com/business/healthcare-pharmaceuticals/varda-space-raises-187-million-accelerate-development-drugs-space-2025-07-10/
- [Varda Space Industries] Company website and mission updates
- [933thedrive.com, Sep 2026] Varda raises $250 million at $1.6 billion valuation to scale orbital drug manufacturing | https://www.933thedrive.com/2026/09/30/varda-raises-250-million-at-1-6-billion-valuation-to-scale-orbital-drug-manufacturing/
- [Varda Space Industries, retrieved 2024] Product and service descriptions
- [LeadIQ, retrieved 2026] Employee count data
- [Fierce Pharma] Report on upcoming Varda missions
- [TechCrunch, November 2025] Varda says it has proven space manufacturing works | https://techcrunch.com/2025/11/30/varda-says-it-has-proven-space-manufacturing-works-now-it-wants-to-make-it-boring/